TY - JOUR
T1 - Paclitaxel-related dermatological problems
T2 - Not only alopecia occurs
AU - Su, Ming Hsuan
AU - Chen, Guan Yeu
AU - Lin, Jun Hung
AU - Lee, Howard Hao
AU - Chung, Kai Cheng
AU - Wang, Peng Hui
N1 - Funding Information:
This work was supported by grants from the Taipei Veterans General Hospital ( V108C-085 ) and from the Ministry of Science and Technology , Executive Yuan (MOST: 106-2314-B-075-061-MY3 ), Taipei, Taiwan. The authors appreciate financial support from the Female Cancer Foundation , Taipei, Taiwan.
Funding Information:
This work was supported by grants from the Taipei Veterans General Hospital (V108C-085) and from the Ministry of Science and Technology, Executive Yuan (MOST: 106-2314-B-075-061-MY3), Taipei, Taiwan. The authors appreciate financial support from the Female Cancer Foundation, Taipei, Taiwan.
Publisher Copyright:
© 2019
PY - 2019/11
Y1 - 2019/11
N2 - Objective: Dermatological problems after chemotherapy are often neglected with gynecological oncologists. Since paclitaxel is one of most popular agents for gynecology organ-related cancers, dermatologic change after paclitaxel treatment is seldom reported before. Case report: Two patients with gynecological organ malignancy who underwent the postoperative dose-dense weekly schedule of paclitaxel 80 mg/m2 plus carboplatin (area of curve 5) every three weeks had repeat dermatological problems (skull, facial and upper trunk areas) during the treatment. They included dermatitis, eczema, and folliculitis. Topical use of anti-fungal cream and oral anti-histamine agents stopped the disease progression and all had completed their chemotherapy without interruption. Conclusion: Clinicians should be aware of paclitaxel-induced skin toxicities, especially on the skull, face and upper trunk areas to minimize the occurrence of severe morbidity and to provide the better quality of life when cure is our primary priority in the management of gynecological organs-related malignancies.
AB - Objective: Dermatological problems after chemotherapy are often neglected with gynecological oncologists. Since paclitaxel is one of most popular agents for gynecology organ-related cancers, dermatologic change after paclitaxel treatment is seldom reported before. Case report: Two patients with gynecological organ malignancy who underwent the postoperative dose-dense weekly schedule of paclitaxel 80 mg/m2 plus carboplatin (area of curve 5) every three weeks had repeat dermatological problems (skull, facial and upper trunk areas) during the treatment. They included dermatitis, eczema, and folliculitis. Topical use of anti-fungal cream and oral anti-histamine agents stopped the disease progression and all had completed their chemotherapy without interruption. Conclusion: Clinicians should be aware of paclitaxel-induced skin toxicities, especially on the skull, face and upper trunk areas to minimize the occurrence of severe morbidity and to provide the better quality of life when cure is our primary priority in the management of gynecological organs-related malignancies.
KW - Dermatological problems
KW - Dose-dense chemotherapy
KW - Folliculitis
KW - Paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=85073016797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073016797&partnerID=8YFLogxK
U2 - 10.1016/j.tjog.2019.08.003
DO - 10.1016/j.tjog.2019.08.003
M3 - Article
C2 - 31759547
AN - SCOPUS:85073016797
SN - 1028-4559
VL - 58
SP - 877
EP - 879
JO - Taiwanese Journal of Obstetrics and Gynecology
JF - Taiwanese Journal of Obstetrics and Gynecology
IS - 6
ER -
